Darunavir was designed for a specific problem: people whose virus had become resistant to the existing protease inhibitors. The trials that established it are unusual in having recruited exactly that group.
What did the POWER studies show?
These trials tested boosted darunavir in heavily treatment-experienced people with extensive protease inhibitor resistance. A substantial proportion achieved viral suppression that had not been achievable on other regimens, which was the finding that established the drug.
What did ARTEMIS show?
A trial in people starting treatment, comparing boosted darunavir with boosted lopinavir. Darunavir was at least as effective with better tolerability and fewer gastrointestinal effects, which extended its use from resistant disease to first-line treatment.
What does the resistance data show?
Consistently the strongest in the class. Treatment-emergent resistance to darunavir is rare, and several mutations must accumulate before activity is lost. In many studies of people who did not suppress, no darunavir resistance was detected at all.
How does that compare with integrase inhibitors?
Dolutegravir and bictegravir also have high barriers, so darunavir no longer stands alone in this respect. Comparative trials favour the integrase inhibitors on tolerability and speed of suppression, without a meaningful difference in eventual outcome.
What about monotherapy?
Studies tested boosted darunavir alone as maintenance in suppressed people, on the basis of its resistance barrier. Results were mixed, with higher rates of low-level rebound than standard combinations, and the approach is not recommended.
What about two-drug regimens?
Combinations of boosted darunavir with a single other agent have been studied and used in specific situations, particularly where a nucleoside backbone is unsuitable. These are specialist choices rather than general practice.
What did the single-tablet studies show?
Trials of darunavir co-formulated with cobicistat, emtricitabine and tenofovir alafenamide found suppression maintained on switching, with the convenience of one tablet. That product made boosted protease inhibitor therapy considerably simpler.
What about lipids?
Boosted darunavir raises cholesterol and triglycerides, less than older protease inhibitors and more than integrase inhibitors. Over years that contributes to cardiovascular risk, and it is monitored routinely.
What about pregnancy?
Studies have shown levels falling in the later stages, which is why twice-daily dosing with ritonavir is often preferred during pregnancy rather than once-daily boosted with cobicistat.
What is still being studied?
Mainly its role in simplified regimens and in resource-limited settings, where its robustness against imperfect adherence is particularly valuable. Its core properties are well established.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.
How do trials differ from real life?
Trial participants are monitored closely, reminded about appointments and selected for having few other conditions. Real-world results for darunavir are usually slightly less impressive as a consequence, and the gap reflects the setting rather than the drug.
Where does the funding come from?
Much antiretroviral research is industry-funded, which is normal and worth knowing. Independent cohort studies and guideline committees exist partly to scrutinise it, and findings about darunavir that appear across both are the most reliable.
Does new evidence change practice quickly?
Slowly, and deliberately. Guidelines change when several studies point the same way rather than after a single result. If you read something striking about darunavir, it is worth asking your clinic whether it has changed anything before acting on it.
What is not known?
Effects over several decades, since darunavir has not been in use that long in the way older drugs have. That is not a warning, and it is a reason the monitoring continues rather than tapering off once things are stable.
How should you read a headline about it?
Sceptically. Reports about antiretrovirals frequently describe early findings, small studies or results from other countries. Checking the claim against NAM aidsmap or asking your clinic is quicker than working out the study design yourself.